RT Journal Article
SR Electronic
T1 THE MS-SMART TRIAL IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS: A MULTI-ARM, MULTI-CENTRE TRIAL OF NEUROPROTECTION
JF Journal of Neurology, Neurosurgery & Psychiatry
JO J Neurol Neurosurg Psychiatry
FD BMJ Publishing Group Ltd
SP e4
OP e4
DO 10.1136/jnnp-2015-312379.105
VO 86
IS 11
A1 Jeremy Chataway
A1 Siddharthan Chandran
A1 David Miller
A1 Gavin Giovannoni
A1 Claudia Wheeler-Kingshott
A1 Sue Pavitt
A1 Nigel Stallard
A1 Clive Hawkins
A1 Basil Sharrack
A1 for the MS-SMART trialists
YR 2015
UL http://jnnp.bmj.com/content/86/11/e4.8.abstract
AB There is currently no treatment for secondary progressive multiple sclerosis (SPMS) which determines the majority of disability in multiple sclerosis. The MS-SMART trial is a multi-arm, multi-centre, phase 2 randomised trial for patients with SPMS. A total of 440 patients with progressing SPMS will be recruited in England and Scotland and randomised to one of 4 blinded arms: amiloride 5mg bd, riluzole 50mg bd, fluoxetine 20mg bd or placebo. These agents have been chosen after an extensive systematic review which has suggested putative neuroprotective properties. Patients will be followed up for 96 weeks with outcome data collected after 0, 24, 48 and 96 weeks. The primary endpoint is MRI atrophy rate. A wide range of relevant secondary and mechanistic exploratory outcomes will be collected including: MR spectroscopy, MTR, grey matter volume cervical cord atrophy, CSF neurofilament levels and optical coherence tomography. This trial is now open for recruitment in 2015.This independent research is awarded by the Efficacy and Mechanism Evaluation Programme (EME) and funded by the Medical Research Council (MRC) and the Multiple Sclerosis Society (MS Society) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership.